Meanwhile, MTHFD2 promotes PD-L1-mediated tumor immunoresistance through the folate cycle-HBP metabolic pathway and the UDP-GlcNAc-O-GlcNAcylation-MYC-PD-L1 signaling pathway. Here, MYC is linked to neoplasm.